Seeking Alpha
 

Micromet, Inc. (MITI)

- NASDAQ
MITI is defunct.
  • Jul. 11, 2011, 9:13 AM
    Micromet (MITI) says it entered into a collaboration agreement with Amgen (AMGN) for the research of BiTE antibodies designed to direct the body's cell-destroying T-cells against tumor cells, representing a new therapeutic approach to cancer therapy. MITI +4.5%, AMGN -0.8% premarket. (PR)
    | Comment!
  • Jul. 11, 2011, 9:05 AM
    Premarket gainers: ARJ +11%. AIS +8%. PSTI +6%. MITI +4%. SIRI +3%.
    Losers: ING -7%. NBG -6%. BBVA -6%. STD -5%. IRE -5%. TEF -5%. TEF -5%. RENN -5%. E -5%. BCS -4%. DB -4%. LYG -4%. TS -4%. ALU -4%. CTIC -4%. NOK -4%. BUD -4%. TOT -4%. TSEM -4%. SI -3%. FRO -3%. CPST -3%. MT -3%. SDRL -3%. RCL -3%. CS -3%. STO -3%. AMD -3%. UN -3%. SINA -3%.
    | Comment!
  • Jun. 10, 2011, 8:54 AM
    Micromet (MITI +11.5%) says 75% of patients in a small phase-2 trial of its leukemia treatment blinatumomab achieved a complete remission, with no remaining cells in blood or bone marrow. MITI says the results are particularly striking given that the majority of enrolled patients had characteristics typically associated with a dismal outlook. (PR)
    | Comment!
Visit Seeking Alpha's
Company Description
Currently, there's no company description for MITI.
Sector: Healthcare
Industry: Biotechnology
Country: United States